FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890826024> ?p ?o ?g. }

• W2890826024 endingPage "vi10" @default.
• W2890826024 startingPage "vi10" @default.
• W2890826024 abstract "Background: STAMPEDE is a multi-arm, multi-stage (MAMS) platform protocol. It has recruited more than 10,000 patients since 2005. Hormone-sensitive metastatic or locally advanced prostate cancer patients starting androgen deprivation therapy (ADT) have been randomised between a number of experimental treatment pairings, including docetaxel or abiraterone, shown to improve overall survival. Funded by PCUK, the STRATOSPHERE consortium (Stratification for rational treatment-oncomarker pairings of STAMPEDE patients starting long-term hormone treatment) has established a framework to enable molecular analyses of archival tissue from these patients. We present the optimised work-flow and preliminary data on feasibility of next-generation sequencing (NGS) of FFPE archival samples. Methods: Approximately 95% of patients participating in STAMPEDE have consented to donate their archival tissue for research. Retrospective tumour block acquisition started in March 2017 and is ongoing. To date, FFPE blocks from 1310 (35%) consenting patients randomised between ADT and abiraterone and docetaxel +/- zoledronic acid comparison arms (3909 total participants) have been retrieved from 64/112 STAMPEDE sites. Results: Morphological review has identified cancer in 86% of cores. DNA and RNA from alternate sections have been extracted using the Zymo Quick-DNA and Quick-RNA FFPE kits. The mean amount of DNA obtained per core was 23ng (range: 0-82ng) from a mean of 8 sections (range 2-14) at 10um thickness per block. DNA has been subjected to low-pass whole genome sequencing and analyses of the first 100 cores from participants recruited to the SOC arm is ongoing. RNA is being extracted from cores with >50% cellularity and >60% tumour content to assess transcriptomic changes and integrate with genomic data. Conclusions: The STRATOSPHERE consortium is addressing the challenge of exploiting FFPE material with low-output, poor-quality nucleic acids from a clinically-important randomised cohort with long-term follow-up. Molecular data will be linked to clinical outcome to test differences in treatment effect by molecular sub-type. Legal entity responsible for the study: University College London. Funding: Prostate Cancer UK. Disclosure: C. Gilson: Grant support from Clovis Oncology. N. James: Grant support, drug supplies and distribution, lecture fees, and advisory board fees from Astellas Pharma and Novartis, grant support, drug supplies and distribution, and lecture fees from Pfizer, grant support, drug supplies and distribution from Clovis Oncology, and grant support, discounted drug supplies, lecture fees, advisory board fees, and travel assistance from Sanofi-Aventis. N.W. Clarke: Receives consulting fees, fees for serving on an advisory board, and lecture fees from Janssen Pharmaceuticals. M. Sydes, M.K.B. Parmar: Grant support and drug supplies and distribution from Astellas Pharma, Clovis Oncology, Novartis, Pfizer, and Sanofi-Aventis. S. Chowdhury: Honoraria, lecture fees, and travel support from Janssen Pharmaceuticals. R.J. Jones: Lecture fees, fees for serving on an advisory board, and publication and writing support from Janssen and grant support, lecture fees, and fees for serving on an advisory board from Astellas Pharma. D. Berney: Has acted as advisor for AstraZeneca, Merck and Roche and has been paid a grant by Myriad genetics for validation of their Prolaris RNA based test for early prostate cancer. G. Attard: Consulting fees from Veridex, Novartis, and Millennium Pharmaceuticals, consulting fees, lecture fees, and travel support from Roche/Ventana Medical Systems and Astellas Pharma, consulting fees and travel support from Medivation, Abbott Laboratories, ESSA Pharma, and Bayer HealthCare Pharmaceuticals, lecture fees from Sanofi-Aventis and Takeda, grant support from AstraZeneca, Arno Therapeutics, and Innocrin Pharmaceuticals, and royalties for a patent on “17-substituted steroids useful in cancer treatment” (GB9305269) being licensed by Janssen Pharmaceuticals. All other authors have declared no conflicts of interest." @default.
• W2890826024 created "2018-09-27" @default.
• W2890826024 creator A5000156180 @default.
• W2890826024 creator A5006350937 @default.
• W2890826024 creator A5011222815 @default.
• W2890826024 creator A5016398935 @default.
• W2890826024 creator A5019948461 @default.
• W2890826024 creator A5022016280 @default.
• W2890826024 creator A5028032356 @default.
• W2890826024 creator A5028957065 @default.
• W2890826024 creator A5030127557 @default.
• W2890826024 creator A5033521569 @default.
• W2890826024 creator A5042462233 @default.
• W2890826024 creator A5048796030 @default.
• W2890826024 creator A5056012644 @default.
• W2890826024 creator A5059261043 @default.
• W2890826024 creator A5065195021 @default.
• W2890826024 creator A5074080812 @default.
• W2890826024 creator A5075114247 @default.
• W2890826024 creator A5076641501 @default.
• W2890826024 creator A5082741959 @default.
• W2890826024 creator A5087334117 @default.
• W2890826024 date "2018-09-01" @default.
• W2890826024 modified "2023-09-27" @default.
• W2890826024 title "Implementing molecular characterisation of prostate cancer tissue from patients recruited to the multi-centre STAMPEDE trial: The STRATOSPHERE consortium" @default.
• W2890826024 doi "https://doi.org/10.1093/annonc/mdy318.011" @default.
• W2890826024 hasPublicationYear "2018" @default.
• W2890826024 type Work @default.
• W2890826024 sameAs 2890826024 @default.
• W2890826024 citedByCount "0" @default.
• W2890826024 crossrefType "journal-article" @default.
• W2890826024 hasAuthorship W2890826024A5000156180 @default.
• W2890826024 hasAuthorship W2890826024A5006350937 @default.
• W2890826024 hasAuthorship W2890826024A5011222815 @default.
• W2890826024 hasAuthorship W2890826024A5016398935 @default.
• W2890826024 hasAuthorship W2890826024A5019948461 @default.
• W2890826024 hasAuthorship W2890826024A5022016280 @default.
• W2890826024 hasAuthorship W2890826024A5028032356 @default.
• W2890826024 hasAuthorship W2890826024A5028957065 @default.
• W2890826024 hasAuthorship W2890826024A5030127557 @default.
• W2890826024 hasAuthorship W2890826024A5033521569 @default.
• W2890826024 hasAuthorship W2890826024A5042462233 @default.
• W2890826024 hasAuthorship W2890826024A5048796030 @default.
• W2890826024 hasAuthorship W2890826024A5056012644 @default.
• W2890826024 hasAuthorship W2890826024A5059261043 @default.
• W2890826024 hasAuthorship W2890826024A5065195021 @default.
• W2890826024 hasAuthorship W2890826024A5074080812 @default.
• W2890826024 hasAuthorship W2890826024A5075114247 @default.
• W2890826024 hasAuthorship W2890826024A5076641501 @default.
• W2890826024 hasAuthorship W2890826024A5082741959 @default.
• W2890826024 hasAuthorship W2890826024A5087334117 @default.
• W2890826024 hasBestOaLocation W28908260241 @default.
• W2890826024 hasConcept C121608353 @default.
• W2890826024 hasConcept C126322002 @default.
• W2890826024 hasConcept C143998085 @default.
• W2890826024 hasConcept C2776421732 @default.
• W2890826024 hasConcept C2777899217 @default.
• W2890826024 hasConcept C2780192828 @default.
• W2890826024 hasConcept C2781190966 @default.
• W2890826024 hasConcept C61367390 @default.
• W2890826024 hasConcept C71924100 @default.
• W2890826024 hasConceptScore W2890826024C121608353 @default.
• W2890826024 hasConceptScore W2890826024C126322002 @default.
• W2890826024 hasConceptScore W2890826024C143998085 @default.
• W2890826024 hasConceptScore W2890826024C2776421732 @default.
• W2890826024 hasConceptScore W2890826024C2777899217 @default.
• W2890826024 hasConceptScore W2890826024C2780192828 @default.
• W2890826024 hasConceptScore W2890826024C2781190966 @default.
• W2890826024 hasConceptScore W2890826024C61367390 @default.
• W2890826024 hasConceptScore W2890826024C71924100 @default.
• W2890826024 hasLocation W28908260241 @default.
• W2890826024 hasOpenAccess W2890826024 @default.
• W2890826024 hasPrimaryLocation W28908260241 @default.
• W2890826024 hasRelatedWork W122177069 @default.
• W2890826024 hasRelatedWork W1652439388 @default.
• W2890826024 hasRelatedWork W1898921923 @default.
• W2890826024 hasRelatedWork W2015876133 @default.
• W2890826024 hasRelatedWork W2021751111 @default.
• W2890826024 hasRelatedWork W2162738516 @default.
• W2890826024 hasRelatedWork W2768013934 @default.
• W2890826024 hasRelatedWork W2768688864 @default.
• W2890826024 hasRelatedWork W2935114107 @default.
• W2890826024 hasRelatedWork W3156855168 @default.
• W2890826024 hasVolume "29" @default.
• W2890826024 isParatext "false" @default.
• W2890826024 isRetracted "false" @default.
• W2890826024 magId "2890826024" @default.
• W2890826024 workType "article" @default.